Details of the Drug

General Information of Drug (ID: DMAF1NB)

Drug Name

Isocarboxazid

Synonyms

BMIH; Benazide; Enerzer; Isocarbonazid; Isocarbossazide; Isocarboxazida; Isocarboxazide; Isocarboxazidum; Isocarboxyzid; Maraplan; Marplan; Marplon; Isocarbossazide [DCIT]; Isocarboxazid (INN); Isocarboxazid [INN:BAN]; Isocarboxazida [INN-Spanish]; Isocarboxazide [INN-French]; Isocarboxazidum [INN-Latin]; Marplan (TN); Ro5-0831; Ro 5-0831/1; N'-Benzyl N-methyl-5-isoxazolecarboxylhydrazide-3; N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide; 1-Benzyl-2-(5-methyl-3-isoxazolyl-carbonyl)hydrazine; 1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide; 3-Isoxazolecarboxylic acid, 5-methyl-, 2-benzylhydrazide; 5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide; 5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1], [2]

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

231.25

Topological Polar Surface Area (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 54.5 +/- 9.1% [4]
Elimination: Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 4 hours [6]
Metabolism: The drug is metabolized via the acetylation in the liver [4]

Chemical Identifiers

Formula: C12H13N3O2
IUPAC Name: N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
Canonical SMILES: CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2
InChI: InChI=1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey: XKFPYPQQHFEXRZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3759
ChEBI ID: CHEBI:93635
CAS Number: 59-63-2
DrugBank ID: DB01247
TTD ID: D0I2VK
ACDINA ID: D00331

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type A (MAO-A)	DTT	MAOA	8.14E-01	0.05	0.1

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isocarboxazid

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Isocarboxazid and Vilazodone.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Isocarboxazid and Vortioxetine.	Depression [6A70-6A7Z]	[19]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Isocarboxazid and Milnacipran.	Depression [6A70-6A7Z]	[18]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Isocarboxazid and Desvenlafaxine.	Depression [6A70-6A7Z]	[18]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Isocarboxazid and Esketamine.	Depression [6A70-6A7Z]	[20]
-----------

Coadministration of a Drug Treating the Disease Different from Isocarboxazid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Isocarboxazid and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[21]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-glulisine.	Acute diabete complication [5A2Y]	[22]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-aspart.	Acute diabete complication [5A2Y]	[23]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Amyl nitrite.	Angina pectoris [BA40]	[25]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Levalbuterol.	Asthma [CA23]	[26]
Pirbuterol	DMI5678	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Pirbuterol.	Asthma [CA23]	[27]
Ephedrine	DMMV0KW	Major	Increased risk of hyperpyrexia by the combination of Isocarboxazid and Ephedrine.	Asthma [CA23]	[25]
Lisdexamfetamine	DM6W8V5	Major	Additive hypertensive effects by the combination of Isocarboxazid and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[25]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Droxidopa.	Autonomic nervous system disorder [8D87]	[28]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Arformoterol	DMYM974	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Isocarboxazid and Levomilnacipran.	Chronic pain [MG30]	[18]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Cyclandelate.	Dementia [6D80-6D8Z]	[25]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Isocarboxazid and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[29]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Isocarboxazid and LEVONORDEFRIN.	Discovery agent [N.A.]	[30]
Tetrabenazine	DMYWQ0O	Major	Additive hypertensive effects by the combination of Isocarboxazid and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[31]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Isocarboxazid and Deutetrabenazine.	Dystonic disorder [8A02]	[31]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Isocarboxazid and Mephentermine.	Essential hypertension [BA00]	[25]
Solifenacin	DMG592Q	Minor	Additive anticholinergic effects by the combination of Isocarboxazid and Solifenacin.	Functional bladder disorder [GC50]	[32]
Nesiritide	DMFOIA8	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Nesiritide.	Heart failure [BD10-BD1Z]	[25]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Isocarboxazid caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[33]
Maraviroc	DMTL94F	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Aliskiren.	Hypertension [BA00-BA04]	[25]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Levamlodipine.	Hypertension [BA00-BA04]	[25]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and TAK-491.	Hypertension [BA00-BA04]	[25]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Hydralazine.	Hypertension [BA00-BA04]	[25]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Clevidipine butyrate.	Hypertension [BA00-BA04]	[25]
Belladonna	DM2RBWK	Minor	Additive anticholinergic effects by the combination of Isocarboxazid and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[32]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Isocarboxazid and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[34]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Isocarboxazid caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[33]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[35]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Isocarboxazid and Lasmiditan.	Migraine [8A80]	[18]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Flibanserin.	Mood disorder [6A60-6E23]	[36]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Isocarboxazid caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[37]
Dextroamphetamine	DMMIHVP	Major	Additive hypertensive effects by the combination of Isocarboxazid and Dextroamphetamine.	Narcolepsy [7A20]	[25]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Phenindamine.	Nasopharyngitis [CA00]	[24]
Phendimetrazine	DM6TS1N	Major	Increased risk of hyperpyrexia by the combination of Isocarboxazid and Phendimetrazine.	Obesity [5B80-5B81]	[25]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Isocarboxazid and Lorcaserin.	Obesity [5B80-5B81]	[38]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Isocarboxazid caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[33]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Polythiazide.	Oedema [MG29]	[25]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Lofexidine.	Opioid use disorder [6C43]	[25]
Methamphetamine	DMPM4SK	Major	Additive hypertensive effects by the combination of Isocarboxazid and Methamphetamine.	Pain [MG30-MG3Z]	[39]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Silodosin.	Prostate hyperplasia [GA90]	[25]
Levomepromazine	DMIKFEL	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Selexipag.	Pulmonary hypertension [BB01]	[25]
Avanafil	DM75CXN	Moderate	Additive hypotensive effects by the combination of Isocarboxazid and Avanafil.	Sexual dysfunction [HA00-HA01]	[25]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[22]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Isocarboxazid and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[22]
Xylometazoline	DMKV32D	Moderate	Decreased metabolism of Isocarboxazid caused by Xylometazoline mediated inhibition of non-CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[33]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Isocarboxazid and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[24]
-----------


⏷ Show the Full List of 54 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 27	E00381	83511	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Isocarboxazid 10 mg tablet	10 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7204).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011961.
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	SCHWARTZ MA: The metabolism of isocarboxazid (marplan) in the rat. J Pharmacol Exp Ther. 1960 Oct;130:157-65.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
8	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
9	Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
10	Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
11	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
12	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
13	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
14	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
15	Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
16	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
17	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
18	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
19	Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
20	Cerner Multum, Inc. "Australian Product Information.".
21	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
22	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
23	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
24	Canadian Pharmacists Association.
25	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
26	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
27	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
28	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
29	Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
30	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
31	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
32	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
33	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
34	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
35	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
36	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
37	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
38	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
39	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]